Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Acerca de este artículo
Fórmula empírica (notación de Hill):
C23H16N4O
Número CAS:
Peso molecular:
364.40
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleServicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
CDPPB, ≥98% (HPLC)
SMILES string
O.O=C(Nc1cc(nn1-c2ccccc2)-c3ccccc3)c4cccc(c4)C#N
InChI
1S/C23H16N4O.H2O/c24-16-17-8-7-11-19(14-17)23(28)25-22-15-21(18-9-3-1-4-10-18)26-27(22)20-12-5-2-6-13-20;/h1-15H,(H,25,28);1H2
InChI key
GZHZEGYXLNXEBV-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: ≥5 mg/mL at warmed to 60 °C
storage temp.
2-8°C
Quality Level
Categorías relacionadas
Application
CDPPB may be used in mGluR5-mediated cell signaling studies.
Biochem/physiol Actions
Activation of metabotropic glutamate 5 receptor by CDPPB enhances the function of NMDA receptor and markers of neuronal plasticity. This improves recognition memory and cognition deficits in schizophrenia.
CDPPB is a glutamate metabotropic mGluR5 positive allosteric modulator.
CDPPB is an mGluR5 positive allosteric modulator
Features and Benefits
This compound is featured on the Glutamate Receptors (G Protein Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Jason M Uslaner et al.
Neuropharmacology, 57(5-6), 531-538 (2009-07-25)
In the search for strategies to treat schizophrenia, attention has focused on enhancing NMDA receptor function. In vitro experiments show that metabotropic glutamate 5 receptor (mGluR5) activation enhances NMDA receptor activity, and in vivo experiments indicate that mGluR5 positive allosteric
Christina Gobin et al.
Psychopharmacology, 237(1), 115-125 (2019-08-26)
Cocaine use disorder (CUD) remains difficult to treat with no FDA-approved medications to reduce relapse. Antagonism of metabotropic glutamate receptor 5 (mGlu5) has been demonstrated to decrease cocaine-seeking but may also further compromise cognitive function in long-term cocaine users. Here we
Hyejin Lee et al.
PLoS biology, 17(6), e2005326-e2005326 (2019-06-06)
Netrin-G ligand-3 (NGL-3) is a postsynaptic adhesion molecule known to directly interact with the excitatory postsynaptic scaffolding protein postsynaptic density-95 (PSD-95) and trans-synaptically with leukocyte common antigen-related (LAR) family receptor tyrosine phosphatases to regulate presynaptic differentiation. Although NGL-3 has been
J G Doria et al.
British journal of pharmacology, 169(4), 909-921 (2013-03-16)
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by a polyglutamine expansion in the huntingtin protein. We have previously demonstrated that the cell signalling of the metabotropic glutamate receptor 5 (mGluR5) is altered in a mouse model of
Patrick K McCamphill et al.
Science translational medicine, 12(544) (2020-05-22)
Fragile X syndrome is caused by FMR1 gene silencing and loss of the encoded fragile X mental retardation protein (FMRP), which binds to mRNA and regulates translation. Studies in the Fmr1-/y mouse model of fragile X syndrome indicate that aberrant
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico